A randomized trial of the effect of vitamin E on plasma prostacyclin (6-keto-PGF1 alpha) levels in healthy adults.
We conducted a randomized, placebo-controlled double blind trial of the effect of vitamin E (800 IU/day) on plasma prostacyclin levels. After drawing baseline blood samples, 30 healthy adults were randomly assigned to vitamin E or placebo. After eight weeks, we again collected blood and assayed the plasma for 6-keto-PGF1 alpha, the principal stable degradation product of prostacyclin. Mean levels of 6-keto-PGF1 alpha in those patients who received placebo was essentially unchanged, 27 pg/ml at baseline and 29 pg/ml at 8 weeks. The mean level of those patients on vitamin E declined dramatically, from 29 to 13 pg/ml. The mean net difference due to vitamin E, -18 pg/ml (95% confidence limits from -32 to -3), was statistically significant, p = .02. It is not clear whether this effect is restricted to prostacyclin or if vitamin E exerts a similar tendency on other arachidonic acid derived products.